X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SHASUN PHARMA NATCO PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 16.0 123.9 12.9% View Chart
P/BV x 17.2 8.5 201.6% View Chart
Dividend Yield % 0.7 0.2 285.3%  

Financials

 NATCO PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
SHASUN PHARMA
Mar-14
NATCO PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs87794 931.0%   
Low Rs42446 928.7%   
Sales per share (Unadj.) Rs223.4214.2 104.3%  
Earnings per share (Unadj.) Rs31.15.3 582.2%  
Cash flow per share (Unadj.) Rs40.315.8 254.6%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.81.4 53.7%  
Book value per share (Unadj.) Rs219.553.3 411.5%  
Shares outstanding (eoy) m33.0756.62 58.4%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.3 891.7%   
Avg P/E ratio x20.913.1 159.8%  
P/CF ratio (eoy) x16.14.4 365.4%  
Price / Book Value ratio x3.01.3 226.1%  
Dividend payout %16.118.7 85.9%   
Avg Mkt Cap Rs m21,5043,958 543.3%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1282,164 52.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,38912,127 60.9%  
Other income Rs m167229 72.9%   
Total revenues Rs m7,55612,356 61.2%   
Gross profit Rs m1,7931,009 177.7%  
Depreciation Rs m304594 51.3%   
Interest Rs m366415 88.2%   
Profit before tax Rs m1,290230 561.5%   
Minority Interest Rs m460-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309-73 -424.5%   
Profit after tax Rs m1,027302 340.1%  
Gross profit margin %24.38.3 291.7%  
Effective tax rate %23.9-31.7 -75.6%   
Net profit margin %13.92.5 558.1%  
BALANCE SHEET DATA
Current assets Rs m3,6816,884 53.5%   
Current liabilities Rs m3,1238,456 36.9%   
Net working cap to sales %7.6-13.0 -58.3%  
Current ratio x1.20.8 144.8%  
Inventory Days Days8962 145.2%  
Debtors Days Days59108 54.6%  
Net fixed assets Rs m7,6854,970 154.6%   
Share capital Rs m331113 291.9%   
"Free" reserves Rs m6,6702,875 232.0%   
Net worth Rs m7,2593,020 240.3%   
Long term debt Rs m9551,817 52.5%   
Total assets Rs m11,95713,347 89.6%  
Interest coverage x4.51.6 291.1%   
Debt to equity ratio x0.10.6 21.9%  
Sales to assets ratio x0.60.9 68.0%   
Return on assets %11.75.4 216.9%  
Return on equity %14.210.0 141.5%  
Return on capital %20.713.3 155.6%  
Exports to sales %39.446.4 84.9%   
Imports to sales %5.714.2 40.0%   
Exports (fob) Rs m2,9085,622 51.7%   
Imports (cif) Rs m4211,728 24.4%   
Fx inflow Rs m3,4455,843 59.0%   
Fx outflow Rs m7032,173 32.3%   
Net fx Rs m2,7433,669 74.7%   
CASH FLOW
From Operations Rs m1,440398 362.2%  
From Investments Rs m-1,089-1,635 66.6%  
From Financial Activity Rs m-3531,309 -27.0%  
Net Cashflow Rs m-171 -2.1%  

Share Holding

Indian Promoters % 52.0 39.2 132.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.6 217.8%  
FIIs % 16.6 17.6 94.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 39.6 65.7%  
Shareholders   25,395 20,750 122.4%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note; Banking and Healthcare Stocks Witness Buying Interest(Closing)

Indian share markets ended their session on a positive note today. Gains were largely seen in the banking sector and healthcare sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 25, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS